Location
Palo Alto, CA
Incident
January 1, 2003
Resolved
January 3, 2022
Status
ConvictedType
fraud
Elizabeth Holmes founded Theranos in 2003, claiming to revolutionize blood testing with finger-prick technology. The company reached a $9 billion valuation before journalist John Carreyrou exposed its fraudulent claims in 2015. Holmes was charged by the SEC in 2018, indicted on federal wire fraud charges, convicted on 4 of 11 counts in January 2022, and sentenced to 11.25 years in prison. She reported to Federal Prison Camp Bryan in Texas on May 30, 2023. Her former COO Sunny Balwani was convicted on all 12 counts and sentenced to nearly 13 years.
In 2003, Elizabeth Holmes dropped out of Stanford University at the age of 19 to found a company initially called Real-Time Cures, which she soon renamed Theranos -- a portmanteau of "therapy" and "diagnosis" [1]. Holmes claimed that Theranos had developed revolutionary blood-testing technology capable of running hundreds of diagnostic tests from just a few drops of blood obtained through a simple finger prick, rather than the traditional vials drawn from a vein [1]. The promise was transformative: faster, cheaper, and less invasive lab work that could be performed at pharmacies and retail locations, democratizing access to diagnostic testing.
The vision attracted enormous investment and attention. By 2013, Theranos had secured a partnership with Walgreens to open in-store Wellness Centers, beginning with a location in Palo Alto, California, with plans to expand nationally [2]. A parade of high-profile investors poured money into the company, including Oracle co-founder Larry Ellison, media mogul Rupert Murdoch, and the Walton family. Theranos assembled a board of directors that read like a who's who of Washington power brokers, featuring former Secretaries of State Henry Kissinger and George Shultz, former Secretary of Defense James Mattis, and former Senators Sam Nunn and Bill Frist [1]. By 2014, the company had raised more than $700 million and achieved a peak valuation of approximately $9 billion, making Holmes -- on paper -- the youngest self-made female billionaire in America [1][3].
The facade began to crack in October 2015 when Wall Street Journal reporter John Carreyrou published a devastating investigation revealing that Theranos was performing only a small fraction of its advertised 240 tests on its proprietary Edison device [2]. The majority of tests, Carreyrou reported, were actually being run on conventional third-party machines manufactured by companies like Siemens, directly contradicting the company's central claims. Carreyrou's reporting, which would eventually form the basis of his bestselling book "Bad Blood," was built on tips from whistleblowers inside Theranos, including former employees who had raised concerns about the accuracy and reliability of the company's technology [2].
Regulatory consequences followed swiftly. In January 2016, the Centers for Medicare and Medicaid Services (CMS) declared that Theranos's Newark, California laboratory had placed patients in "immediate jeopardy" by failing to comply with federal standards [4]. In July 2016, CMS revoked the lab's operating license, banned Holmes from owning or operating any clinical laboratory for at least two years, and canceled the lab's approval to receive Medicare and Medicaid payments [4]. In June 2016, Walgreens terminated its partnership with Theranos and closed all 40 Wellness Centers that had been operating in Arizona [2][4].
On March 14, 2018, the Securities and Exchange Commission charged Theranos, Holmes, and former company president Ramesh "Sunny" Balwani with raising more than $700 million from investors through what the agency described as "massive fraud" [3][5]. The SEC alleged that Holmes and Balwani knew their proprietary analyzer could perform only 12 of the 200 tests published on the company's patient testing menu. Holmes settled with the SEC, agreeing to pay a $500,000 penalty, relinquish her voting control of Theranos, return 18.9 million shares, and accept a 10-year ban from serving as an officer or director of a public company [3][5].
Three months later, on June 15, 2018, a federal grand jury in the Northern District of California returned a criminal indictment charging both Holmes and Balwani with two counts of conspiracy to commit wire fraud and nine counts of wire fraud for their roles in schemes to defraud both investors and patients [2]. Each count carried a maximum penalty of 20 years in prison.
Holmes's criminal trial began on September 8, 2021, in San Jose, California, before U.S. District Judge Edward Davila [6]. Over three months, jurors heard testimony from 32 witnesses, including Holmes herself, who spent seven days on the stand [6]. On January 3, 2022, the jury of eight men and four women, after seven days of deliberation, found Holmes guilty on four of 11 counts: three counts of wire fraud and one count of conspiracy to commit wire fraud, all related to defrauding investors [6][7]. She was acquitted on four counts related to defrauding patients, and the jury deadlocked on three remaining investor fraud counts [6][7].
On November 18, 2022, Judge Davila sentenced Holmes to 11 years and 3 months in federal prison, plus three years of supervised release [7][8]. The sentence fell between the prosecution's request of 15 years and the defense team's plea for no more than 18 months of home confinement. Holmes reported to Federal Prison Camp Bryan, a minimum-security women's facility in Bryan, Texas, on May 30, 2023, to begin serving her sentence [8].
Balwani, who had served as Theranos's president and chief operating officer and had been in a secret romantic relationship with Holmes, was tried separately. On July 7, 2022, a jury convicted Balwani on all 12 counts he faced: 10 counts of wire fraud and two counts of conspiracy to commit wire fraud, encompassing fraud against both investors and patients [9][10]. On December 7, 2022, he was sentenced to nearly 13 years -- 155 months -- in prison, along with three years of probation [9][10]. He was also ordered to pay restitution. Balwani's sentence exceeded Holmes's, reflecting the jury's finding that he had defrauded patients in addition to investors [9][10].
The Theranos case became a defining cautionary tale about the dangers of unchecked hype in Silicon Valley, the failure of corporate governance, and the consequences of prioritizing a compelling narrative over scientific rigor. Holmes and Balwani were jointly ordered to pay $452 million in restitution to the victims of the fraud [1].
On March 14, 2018, the Securities and Exchange Commission filed a civil complaint charging Theranos Inc., CEO Elizabeth Holmes, and former president Ramesh "Sunny" Balwani with conducting a "massive fraud" that raised more than $700 million from investors through false and misleading statements about the company's technology, business performance, and financial condition [1][2]. The SEC alleged that Holmes and Balwani knew that Theranos's proprietary blood analyzer could perform only 12 of the approximately 200 tests published on the company's patient testing menu, yet they repeatedly misrepresented its capabilities in investor presentations, product demonstrations, and media appearances [1][2].
Holmes settled with the SEC without admitting or denying the allegations. Under the terms of the settlement, she agreed to pay a $500,000 civil penalty, surrender 18.9 million shares of Theranos stock, relinquish her super-majority voting control by converting her Class B shares to Class A shares, and accept a 10-year bar from serving as an officer or director of any public company [1][2]. The SEC proceeded with its case against Balwani separately in federal court in San Francisco.
On June 15, 2018, a federal grand jury in the United States District Court for the Northern District of California returned a criminal indictment charging both Holmes and Balwani with two counts of conspiracy to commit wire fraud and nine counts of wire fraud -- 11 counts total [3]. The indictment described two distinct fraud schemes: one targeting investors who were deceived about the capabilities and commercial viability of Theranos's technology, and one targeting patients and doctors who relied on inaccurate test results for medical decisions. Each count carried a maximum statutory penalty of 20 years in prison and a $250,000 fine, plus restitution [3].
Holmes's trial commenced on September 8, 2021, before U.S. District Judge Edward Davila in the Northern District of California in San Jose [4]. The trial lasted approximately three months, with testimony from 32 witnesses. Holmes took the stand in her own defense, testifying over seven days [4]. On January 3, 2022, after seven days of deliberation, the jury returned a mixed verdict: guilty on four counts (three counts of wire fraud and one count of conspiracy to commit wire fraud, all involving investor victims), not guilty on four counts (all patient-related charges), and deadlocked on three remaining investor fraud counts [3][4].
On November 18, 2022, Judge Davila sentenced Holmes to 135 months -- 11 years and 3 months -- in federal prison, followed by three years of supervised release [5]. Federal prosecutors had sought 15 years; Holmes's defense team had requested no more than 18 months of home confinement [5]. Holmes reported to Federal Prison Camp Bryan, a minimum-security women's facility in Bryan, Texas, on May 30, 2023 [6].
Balwani was tried separately from Holmes. On July 7, 2022, a jury convicted him on all 12 counts he faced: 10 counts of wire fraud and two counts of conspiracy to commit wire fraud [7][8]. Unlike Holmes, Balwani was found guilty of defrauding both investors and patients. On December 7, 2022, Judge Davila sentenced Balwani to 155 months -- approximately 12 years and 11 months -- in prison, plus three years of probation [7][8]. Balwani was ordered to pay restitution to defrauded investors [8].
Holmes and Balwani were jointly ordered to pay $452 million in restitution to the victims of the fraud [5].
November 18, 2022
Judge Edward Davila sentences Elizabeth Holmes to 135 months in federal prison — among the longest sentences for a white-collar crime conviction in Silicon Valley history.
Source →January 3, 2022
After a four-month trial, a federal jury convicts Elizabeth Holmes on one count of conspiracy to commit fraud against investors and three counts of wire fraud. She is acquitted on four patient-related charges.
Source →June 15, 2018
A federal grand jury in San Jose indicts Elizabeth Holmes and Sunny Balwani on nine counts of wire fraud and two counts of conspiracy to commit wire fraud related to defrauding investors and patients.
Source →October 16, 2015
John Carreyrou publishes a bombshell investigation in The Wall Street Journal revealing that Theranos's proprietary Edison device is unreliable and the company has been secretly using conventional machines for the majority of its tests.
Source →September 9, 2013
Theranos announces a partnership with Walgreens to offer blood testing at retail pharmacy locations, beginning in Palo Alto and later expanding to Arizona. The company is valued at $9 billion.
Source →September 1, 2003
Elizabeth Holmes, 19, drops out of Stanford University and founds Real-Time Cures, later renamed Theranos (a portmanteau of "therapy" and "diagnosis"), with the stated goal of revolutionizing blood testing.
Source →Relationship data not yet mapped — nodes positioned by force simulation.
Ramesh "Sunny" Balwani
Former president and COO of Theranos and Holmes's former romantic partner. Convicted on all 12 counts of fraud in July 2022 and sentenced to nearly 13 years in prison.
Elizabeth Holmes
Founder and former CEO of Theranos. Convicted of wire fraud and conspiracy in January 2022 for deceiving investors about the capabilities of Theranos blood-testing technology. Sentenced to over 11 years in federal prison.
John Carreyrou
Wall Street Journal investigative reporter who exposed the Theranos fraud in a series of articles beginning in October 2015. He later authored the bestselling book "Bad Blood: Secrets and Lies in a Silicon Valley Startup."